Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.03
(3.57%)
HKD 0.03
(3.57%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 12.8 Million HKD | -96.52% |
| 2022 | 368.14 Million HKD | -12.84% |
| 2021 | 422.36 Million HKD | -9.49% |
| 2020 | 466.62 Million HKD | 26.66% |
| 2019 | 368.4 Million HKD | 70884.01% |
| 2018 | 519 Thousand HKD | -99.71% |
| 2017 | 177.39 Million HKD | 8.75% |
| 2016 | 163.12 Million HKD | 0.0% |
| 2015 | - HKD | -100.0% |
| 2014 | 185 Million HKD | 181.37% |
| 2013 | 65.75 Million HKD | 56.11% |
| 2012 | 42.11 Million HKD | 42.77% |
| 2011 | 29.5 Million HKD | -65.53% |
| 2010 | 85.58 Million HKD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 179 Million HKD | 0.0% |
| 2023 Q1 | 250.37 Million HKD | -31.99% |
| 2023 Q3 | 228.14 Million HKD | -8.88% |
| 2023 Q2 | 250.37 Million HKD | 0.0% |
| 2023 Q4 | 12.8 Million HKD | -94.39% |
| 2023 FY | 12.8 Million HKD | -96.52% |
| 2022 Q2 | 339.01 Million HKD | 0.0% |
| 2022 FY | 368.14 Million HKD | -12.84% |
| 2022 Q4 | 368.14 Million HKD | 0.0% |
| 2022 Q3 | 368.14 Million HKD | 8.59% |
| 2022 Q1 | 339.01 Million HKD | -19.73% |
| 2021 Q2 | 446.71 Million HKD | 0.0% |
| 2021 Q1 | 446.71 Million HKD | -4.27% |
| 2021 Q4 | 422.36 Million HKD | 0.0% |
| 2021 FY | 422.36 Million HKD | -9.49% |
| 2021 Q3 | 422.36 Million HKD | -5.45% |
| 2020 Q2 | 437.92 Million HKD | 0.0% |
| 2020 FY | 466.62 Million HKD | 26.66% |
| 2020 Q3 | 466.62 Million HKD | 6.55% |
| 2020 Q4 | 466.62 Million HKD | 0.0% |
| 2020 Q1 | 437.92 Million HKD | 18.87% |
| 2019 Q3 | 368.4 Million HKD | -12.68% |
| 2019 Q2 | 421.89 Million HKD | 0.0% |
| 2019 Q1 | 421.89 Million HKD | 81189.6% |
| 2019 Q4 | 368.4 Million HKD | 0.0% |
| 2019 FY | 368.4 Million HKD | 70884.01% |
| 2018 Q4 | 519 Thousand HKD | 0.0% |
| 2018 Q2 | 1.11 Million HKD | 0.0% |
| 2018 FY | 519 Thousand HKD | -99.71% |
| 2018 Q1 | 1.11 Million HKD | -99.37% |
| 2018 Q3 | 519 Thousand HKD | -53.49% |
| 2017 Q1 | 170.57 Million HKD | 4.56% |
| 2017 Q4 | 177.39 Million HKD | 0.0% |
| 2017 Q3 | 177.39 Million HKD | 4.0% |
| 2017 FY | 177.39 Million HKD | 8.75% |
| 2017 Q2 | 170.57 Million HKD | 0.0% |
| 2016 Q2 | - HKD | 0.0% |
| 2016 FY | 163.12 Million HKD | 0.0% |
| 2016 Q3 | 163.12 Million HKD | 0.0% |
| 2016 Q1 | - HKD | 0.0% |
| 2016 Q4 | 163.12 Million HKD | 0.0% |
| 2015 Q1 | - HKD | -100.0% |
| 2015 Q4 | - HKD | 0.0% |
| 2015 Q3 | - HKD | 0.0% |
| 2015 Q2 | - HKD | 0.0% |
| 2015 FY | - HKD | -100.0% |
| 2014 Q4 | 185 Million HKD | 0.0% |
| 2014 Q3 | 185 Million HKD | 0.0% |
| 2014 Q1 | 185 Million HKD | 181.37% |
| 2014 FY | 185 Million HKD | 181.37% |
| 2014 Q2 | 185 Million HKD | 0.0% |
| 2013 Q2 | 67.06 Million HKD | 0.0% |
| 2013 Q4 | 65.75 Million HKD | 0.0% |
| 2013 Q3 | 65.75 Million HKD | -1.97% |
| 2013 FY | 65.75 Million HKD | 56.11% |
| 2013 Q1 | 67.06 Million HKD | 59.24% |
| 2012 Q3 | 42.11 Million HKD | 0.0% |
| 2012 Q2 | - HKD | 0.0% |
| 2012 Q4 | 42.11 Million HKD | 0.0% |
| 2012 FY | 42.11 Million HKD | 42.77% |
| 2011 Q4 | 29.5 Million HKD | 0.0% |
| 2011 FY | 29.5 Million HKD | -65.53% |
| 2010 FY | 85.58 Million HKD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -517.511% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 98.707% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 89.071% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 95.365% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | 81.878% |
| Essex Bio-Technology Limited | 36.05 Million HKD | 64.498% |
| PuraPharm Corporation Limited | 81.09 Million HKD | 84.214% |
| SSY Group Limited | 1.94 Billion HKD | 99.343% |
| JBM (Healthcare) Limited | 43.8 Million HKD | 70.774% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 97.838% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.923% |